Global Drug Discovery Mass Spectrometry Market Accelerates Toward USD 1.69 Billion by 2031 | MarketsandMarkets™
High-resolution analytical platforms, proteomics-driven workflows, and expanding CRO outsourcing reshape strategic priorities across pharmaceutical and biotechnology research
Delray Beach, FL, Jan. 22, 2026 (GLOBE NEWSWIRE) -- The global drug discovery mass spectrometry market was valued at USD 0.89 billion in 2024 and is projected to reach USD 1.69 billion by 2031, growing from USD 1.05 billion in 2025, at a CAGR of 8.5% during the forecast period. What is driving this momentum is the growing dependence on high-resolution analytical platforms across pharmaceutical companies, biotechnology firms, and contract research organizations (CROs). Why now? Drug pipelines are shifting toward biologics, precision medicine, and multi-omics strategies that demand deeper molecular insight, faster decision cycles, and reproducible data.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=11784803
Market growth is anchored in the expanding adoption of MS-based proteomics, metabolomics, and structural biology. These technologies enable detailed biological characterization for target identification, mechanism-of-action studies, pathway mapping, and biomarker validation. How does this translate operationally? R&D teams increasingly rely on LC-MS/MS–based lead optimization, ADME profiling, impurity and metabolite identification, and safety assessment to reduce late-stage failures and compress development timelines.
Rising global R&D investment and the rapid expansion of biologics and precision medicine pipelines continue to reinforce demand. At the same time, advances in resolution, acquisition speed, automation, miniaturization, and AI-driven data processing are improving throughput and shortening time-to-insight. Together, these trends are expanding the number of discovery programs built around MS-enabled platforms and positioning mass spectrometry as a strategic enabler of competitive drug development.
Market Drivers: Proteomics as a Strategic Catalyst
One of the most powerful growth drivers is the accelerating adoption of proteomics and targeted proteomics. Who benefits most? Drug developers seeking protein-level insight into disease pathways, drug response, and biomarker behavior. High-resolution MS has become indispensable for identifying and quantifying proteins, post-translational modifications, and pathway changes that cannot be captured through genomics alone.
Targeted approaches such as SRM/MRM, PRM, and DIA are increasingly integrated into translational research, target validation, and lead optimization. These methods deliver accurate, quantitative, and high-throughput biomarker data that strengthens early decision-making and lowers attrition risk. As pipelines move toward complex biologics and precision therapeutics, scalable protein quantification is no longer optional but foundational to R&D strategy.
Market Restraints: Infrastructure Gaps in Developing Regions
Despite strong growth, accessibility remains uneven. In many developing regions, limited laboratory infrastructure restricts the deployment of advanced mass spectrometry systems. What constrains adoption? Unreliable power supply, lack of climate-controlled environments, insufficient technical expertise, and constrained capital budgets. These barriers slow the expansion of MS-based research capabilities, reduce regional participation in global drug discovery programs, and limit the worldwide penetration of advanced analytical technologies.
Market Opportunities: High-Resolution MS in Biopharmaceuticals
Pharmaceutical and biotechnology companies are increasingly investing in high-resolution and accurate mass spectrometry platforms to analyze complex molecules across proteomics, metabolomics, and lipidomics. Why is this critical? These systems deliver superior accuracy, sensitivity, and reproducibility, which are essential for regulatory compliance and advanced biologics characterization.
Organizations deploying high-resolution MS can accelerate R&D timelines, reduce experimental variability, and strengthen data integrity. For MS manufacturers, this trend opens significant opportunities to expand market presence as biopharma research becomes more data-intensive and compliance-driven.
Market Challenges: Standardization and Reproducibility
A persistent challenge across the global market is the lack of standardized protocols between laboratories. Differences in sample preparation, MS platforms, and chromatographic methods often lead to inconsistent results and limited cross-study comparability. For multi-site drug development programs, where harmonized datasets are critical for regulatory submissions, this lack of standardization increases operational costs, delays timelines, and creates adoption hurdles for advanced MS technologies.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=11784803
Ecosystem Overview
The drug discovery mass spectrometry ecosystem spans manufacturers, refurbishers, distributors, and end users. Leading suppliers such as Thermo Fisher Scientific and Agilent Technologies provide high-performance LC-MS/MS and high-resolution systems for screening, metabolite identification, and ADME studies. Refurbishers including Conquer Scientific and GenTech Scientific expand access through validated, cost-effective systems for emerging laboratories and academic centers. Distributors such as HTI and Thomas Scientific strengthen market reach through procurement, installation, and technical support. Pharmaceutical companies, CROs, and research institutes rely on this ecosystem to achieve faster workflows, deeper molecular analysis, and high analytical precision.
Market Segmentation Insights
By product, instruments dominate the market due to high capital requirements and continuous demand for advanced, high-precision platforms. Hybrid systems such as Q-TOF and triple quadrupole mass spectrometers are essential for metabolite profiling, biomarker identification, and pharmacokinetics studies. Frequent technology upgrades driven by automation and throughput requirements further reinforce this segment’s revenue leadership.
By inlet type, LC-MS holds the largest share and remains the gold standard for complex biological matrices. Its ability to separate chemically diverse compounds and detect analytes at trace levels makes it indispensable for PK, DMPK, and metabolite profiling.
By application, proteomics and metabolomics dominate, delivering functional biological insights for precision medicine, toxicoproteomics, and mechanism-of-action studies. High-resolution Orbitrap and Q-TOF systems, combined with AI and machine learning analytics, are significantly enhancing throughput and data interpretation.
By end user, CROs lead adoption as pharmaceutical and biopharmaceutical companies increasingly outsource R&D to control costs and accelerate development. CROs provide access to advanced LC-MS/MS and HRMS systems, specialized expertise, and regulatory-compliant workflows for bioanalysis, pharmacokinetics, and toxicology.
Regional Outlook
The market spans North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is the fastest-growing region, driven by rapid expansion of pharmaceutical, biotechnology, and CRO R&D in China, India, and Southeast Asia. High-throughput MS workflows in proteomics, metabolomics, PK/PD, and bioanalysis are in strong demand, supported by onshoring of analytical laboratories, outsourcing to regional CRDMOs, robust public and private R&D funding, and national biotechnology initiatives.
Competitive Landscape and Recent Developments
Major players include Thermo Fisher Scientific, Agilent Technologies, Waters Corporation, Bruker, Shimadzu Corporation, PerkinElmer, Danaher, MKS Instruments, JEOL, Leco, Advion Interchim Scientific, and Jasco Corporation.
Recent developments underscore the pace of innovation:
- June 2025: Thermo Fisher Scientific unveiled next-generation mass spectrometers at ASMS 2025 to advance biopharma and omics research.
- May 2025: Bruker introduced the timsOmni timsTOF-based system for drug discovery, clinical studies, and biologics quality control.
- June 2023: Thermo Fisher Scientific and Seer Technology partnered to deliver Proteograph XT Assay Kit services on Orbitrap Astral MS, expanding access to deep proteomics studies.
Product launches, collaborations, acquisitions, and strategic partnerships remain the primary growth strategies shaping competitive positioning.
Thermo Fisher Scientific leads the market with its Orbitrap-based platforms, including Q Exactive, Exploris, and Tribrid systems, widely used in proteomics, metabolomics, impurity profiling, and structural elucidation. Agilent Technologies maintains a strong position through its LC-MS portfolio spanning single quadrupole, triple quadrupole, Q-TOF, and ion-mobility-enabled systems for ADME, DMPK, metabolomics, and lead optimization. Danaher, through SCIEX, is recognized for high-sensitivity triple quadrupole and QTRAP systems supporting quantitative bioanalysis and high-throughput workflows.
High switching costs, extensive installed bases, software ecosystems, and continuous innovation in sensitivity and automation create strong entry barriers and reinforce long-term market leadership.
Company and Market Insights
For C-suite leaders, this market evolution signals more than laboratory modernization. It reflects a structural shift in how competitive advantage is built in drug discovery: through data quality, speed of insight, and molecular precision. Organizations that strategically invest in high-resolution MS platforms, standardized workflows, and AI-enabled analytics are better positioned to shorten development cycles, meet regulatory expectations, and differentiate in increasingly complex therapeutic areas.
For more information, Inquire Now!
Discover Connected Healthcare Market Opportunities:
Mass Spectrometry Market
Drug Discovery Services Market
AI in Drug Discovery Market
Proteomics Market
Environmental Mass Spectrometry Market
Get access to the latest updates on Top Companies in Drug Discovery Mass Spectrometry and Drug Discovery Mass Spectrometry Market Size
About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook . Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email: sales@marketsandmarkets.com Visit Our Website: https://www.marketsandmarkets.com/
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
